<?xml version="1.0" encoding="UTF-8"?>
<ref id="b20-1031654">
 <label>20.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Knapper</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Burnett</surname>
    <given-names>AK</given-names>
   </name>
   <name>
    <surname>Littlewood</surname>
    <given-names>T</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>A Phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy</article-title>. 
  <source>Blood</source>. 
  <year>2006</year>;
  <volume>108</volume>(
  <issue>10</issue>):
  <fpage>3262</fpage>â€“
  <lpage>3270</lpage>.
  <pub-id pub-id-type="pmid">16857985</pub-id>
 </mixed-citation>
</ref>
